Nervive is an over-the-counter nerve-support supplement, typically marketed for tingling, burning, or numbness in the hands and feet.
The main ingredients are alpha-lipoic acid and B vitamins (B1, B6, B12), though formulas vary by product line.
Not FDA-approved to diagnose, treat, cure, or prevent neuropathy or any disease.
The oral products are dietary supplements, so their marketing claims—such as “reduction in occasional nerve discomfort in as little as 7 days”—are not held to the same evidence standard as prescription drugs.
Its marketing claims for nerve aches, weakness, and pins-and-needles rest entirely on its component ingredients — most commonly alpha-lipoic acid (ALA), vitamin B12 (as benfotiamine/B-vitamin blend in some formulations), and turmeric/curcumin extract.p
Alpha-lipoic acid has some support for diabetic nerve pain, mostly at around 600 mg/day, but results are modest.
B vitamins help mainly if you’re actually deficient (B12 deficiency is a common cause of neuropathy).
Too much B6 over time can itself cause nerve damage, so check the label and total B6 across all your supplements.
Alpha-lipoic acid can lower blood sugar, which matters if you take diabetes medication.
Possible side effects include nausea, stomach upset, and rash.
The biggest lever is finding the cause (diabetes, B12 deficiency, thyroid issues, alcohol, medications.
Doctors may also prescribe options like duloxetine, gabapentin, or pregabalin, or suggest capsaicin cream.
Nervive Nerve Relief is an over-the-counter dietary supplement, not an FDA-approved drug, and no clinical trials of the branded product itself were identified in the retrieved literature.
The ingredient-level evidence is modest and largely confined to diabetic peripheral neuropathy (DPN), with little to support use in otherwise undifferentiated nerve relief.
Alpha-lipoic acid — the evidence is conflicting and overall weak.
A 2024 Cochrane review of 3 RCTs (816 analyzed adults) concluded ALA probably has little or no effect on neuropathy symptoms at 6 or 24 months, and little or no effect on impairment, with moderate-certainty evidence.
A separate 2026 systematic review/meta-analysis (15 studies) reported significant symptom improvement (paresthesia, numbness, burning) particularly at 600 mg/day, but no change in nerve conduction or HbA1c.
Older landmark trials (SYDNEY2, ALADIN III) showed symptom-score improvement, while the 4-year NATHAN 1 trial missed its composite primary endpoint.
ALA is incorporated into German guidelines for symptomatic diabetic neuropathy, and the ADA notes it may have a role in painful DPN.
The discordance largely reflects short-term symptom scores improving while objective nerve-function measures and long-term endpoints do not.
Vitamin B12 (methylcobalamin/mecobalamin) — benefit is clearest in documented deficiency.
B12 is essential for myelin maintenance; deficiency (vegan diet, atrophic gastritis, pernicious anemia, PPI or metformin use, gastric bypass) causes a sensory-predominant neuropathy that can improve or reverse with repletion.
Standard treatment is 1 mg IM weekly for ~1 month then monthly, or high-dose oral 1–2 mg daily.
In patients with DPN and low B12, 16 weeks of 1000 µg or 2000 µg oral B12 similarly improved neuropathic symptoms.
A meta-analysis found mecobalamin improved clinical symptom outcomes, but nerve conduction velocity improved only with combination therapy, not monotherapy.
Importantly, supplementing B12 without deficiency has limited rationale.
Turmeric/curcumin — essentially no human DPN evidence.
Benefit is almost entirely preclinical (anti-inflammatory, antioxidant, antinociceptive effects in rodent neuropathic pain models).
The only notable human DPN trial used nano-curcumin (80 mg for 8 weeks), showing improved neuropathy scores — a different formulation than standard curcumin supplements.
These supplements are not substitutes for a diagnostic workup.
New or progressive neuropathy warrants evaluation for treatable causes (diabetes/prediabetes, B12 deficiency, thyroid disease, alcohol, paraproteinemia, medications) rather than empiric supplement use.
High-dose B6 is a common additive in “nerve” supplements and can paradoxically cause a sensory neuropathy at chronic high intake — worth checking the specific product’s label and total daily B6.
ALA is generally well tolerated with no significant excess of treatment-limiting adverse events versus placebo in trials.
For symptomatic DPN specifically, the Cochrane forest plot illustrates the lack of long-term benefit from ALA on impairment.
ALA 600 mg daily has some clinical evidence in diabetic peripheral neuropathy, but benefit is generally modest and it is not a substitute for evaluating reversible causes of neuropathy (diabetes/B12 deficiency, thyroid disease, alcohol, medications, autoimmune disease, etc.).
B6 can cause,sensory neuropathy with prolonged high-dose exposure; check total B6 intake from all supplements.
The topical roll-on/cream contains lidocaine and menthol; avoid broken skin, eyes/mucous membranes, and do not use beyond 1 week without clinician advice.
For persistent burning, numbness, weakness, asymmetry, or rapidly progressive symptoms, Nervive is not an adequate diagnostic or therapeutic strategy—work up the neuropathy and treat the underlying cause.
For confirmed mild diabetic neuropathy, ALA may be reasonable as adjunctive therapy; for non-diabetic neuropathy, evidence is less consistent.